Swiss Life Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $45.5M | Buy |
91,614
+9,040
| +11% | +$4.01M | 0.19% | 94 |
|
|
2026
Q1 | $36.9M | Buy |
82,574
+9,556
| +13% | +$4.46M | 0.18% | 103 |
|
|
2025
Q4 | $33.1M | Buy |
73,018
+9,073
| +14% | +$3.91M | 0.17% | 104 |
|
|
2025
Q3 | $25M | Buy |
63,945
+6,045
| +10% | +$2.53M | 0.13% | 120 |
|
|
2025
Q2 | $25.8M | Buy |
57,900
+28,296
| +96% | +$13M | 0.15% | 106 |
|
|
2025
Q1 | $14.4M | Buy |
29,604
+3,938
| +15% | +$1.84M | 0.1% | 156 |
|
|
2024
Q4 | $10.3M | Sell |
25,666
-1,847
| -7% | -$856K | 0.08% | 190 |
|
|
2024
Q3 | $12.8M | Sell |
27,513
-14,596
| -35% | -$7.01M | 0.15% | 135 |
|
|
2024
Q2 | $19.7M | Buy |
42,109
+21,237
| +102% | +$9.22M | 0.23% | 95 |
|
|
2024
Q1 | $8.72M | Sell |
20,872
-21,587
| -51% | -$9.13M | 0.12% | 157 |
|
|
2023
Q4 | $17.3M | Buy |
42,459
+5,372
| +14% | +$1.98M | 0.21% | 111 |
|
|
2023
Q3 | $12.9M | Sell |
37,087
-1,648
| -4% | -$576K | 0.2% | 113 |
|
|
2023
Q2 | $13.6M | Sell |
38,735
-10,463
| -21% | -$3.53M | 0.2% | 119 |
|
|
2023
Q1 | $15.5M | Buy |
49,198
+5,531
| +13% | +$1.66M | 0.23% | 100 |
|
|
2022
Q4 | $12.6M | Buy |
43,667
+4,866
| +13% | +$1.48M | 0.21% | 123 |
|
|
2022
Q3 | $11.2M | Sell |
38,801
-9,478
| -20% | -$2.73M | 0.19% | 137 |
|
|
2022
Q2 | $13.6M | Buy |
48,279
+33,060
| +217% | +$8.85M | 0.22% | 99 |
|
|
2022
Q1 | $3.97M | Buy |
15,219
+108
| +0.7% | +$25.6K | 0.06% | 331 |
|
|
2021
Q4 | $3.32M | Sell |
15,111
-35,848
| -70% | -$6.97M | 0.04% | 379 |
|
|
2021
Q3 | $9.24M | Sell |
50,959
-12,639
| -20% | -$2.47M | 0.13% | 188 |
|
|
2021
Q2 | $12M | Buy |
63,598
+21,006
| +49% | +$4.39M | 0.12% | 156 |
|
|
2021
Q1 | $9.15M | Buy |
42,592
+3,342
| +9% | +$734K | 0.13% | 196 |
|
|
2020
Q4 | $9.28M | Sell |
39,250
-17,871
| -31% | -$4.1M | 0.14% | 176 |
|
|
2020
Q3 | $15.5M | Buy |
57,121
+6,383
| +13% | +$1.76M | 0.23% | 94 |
|
|
2020
Q2 | $14.7M | Buy |
50,738
+3,900
| +8% | +$1.06M | 0.24% | 91 |
|
|
2020
Q1 | $11.1M | Buy |
46,838
+20,419
| +77% | +$4.68M | 0.21% | 99 |
|
|
2019
Q4 | $5.78M | Sell |
26,419
-27,929
| -51% | -$5.65M | 0.11% | 171 |
|
|
2019
Q3 | $9.21M | Sell |
54,348
-8,210
| -13% | -$1.45M | 0.12% | 133 |
|
|
2019
Q2 | $11.5M | Sell |
62,558
-7,261
| -10% | -$1.27M | 0.14% | 123 |
|
|
2019
Q1 | $12.8M | Buy |
69,819
+12,539
| +22% | +$2.32M | 0.16% | 116 |
|
|
2018
Q4 | $9.49M | Sell |
57,280
-3,266
| -5% | -$566K | 0.19% | 124 |
|
|
2018
Q3 | $11.7M | Buy |
60,546
+9,922
| +20% | +$1.77M | 0.16% | 138 |
|
|
2018
Q2 | $8.6M | Sell |
50,624
-8,106
| -14% | -$1.26M | 0.13% | 137 |
|
|
2018
Q1 | $9.57M | Buy |
58,730
+10,913
| +23% | +$1.78M | 0.17% | 132 |
|
|
2017
Q4 | $7.17M | Buy |
47,817
+2,514
| +6% | +$372K | 0.16% | 107 |
|
|
2017
Q3 | $6.89M | Buy |
45,303
+2,064
| +5% | +$311K | 0.18% | 104 |
|
|
2017
Q2 | $5.57M | Hold |
43,239
| – | – | 0.14% | 110 |
|
|
2017
Q1 | $4.73M | Buy |
+43,239
| New | +$3.81M | 0.13% | 111 |
|
|
2016
Q4 | – | Sell |
-54,062
| Closed | -$4.71M | – | 466 |
|
|
2016
Q3 | $4.71M | Hold |
54,062
| – | – | 0.16% | 97 |
|
|
2016
Q2 | $4.65M | Sell |
54,062
-5,068
| -9% | -$438K | 0.19% | 98 |
|
|
2016
Q1 | $4.7M | Buy |
59,130
+2,195
| +4% | +$199K | 0.2% | 99 |
|
|
2015
Q4 | $7.16M | Buy |
56,935
+2,873
| +5% | +$347K | 0.32% | 83 |
|
|
2015
Q3 | $5.63M | Buy |
54,062
+149
| +0.3% | +$19.1K | 0.27% | 92 |
|
|
2015
Q2 | $6.66M | Buy |
53,913
+823
| +2% | +$104K | 0.23% | 82 |
|
|
2015
Q1 | $6.26M | Buy |
+53,090
| New | +$6.36M | 0.25% | 84 |
|
Other funds holding VRTX
N
Swiss Life Asset Management's VRTX Position: Q2 2026 in Review
Swiss Life Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $4.01M and bringing the position to 91,614 shares worth $45.5M. The position accounts for 0.19% of the portfolio, ranked #94.
Swiss Life Asset Management first reported a position in VRTX in Q1 2015 and has held it in 45 quarters since. 1,209 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Swiss Life Asset Management held 91,614 shares of Vertex Pharmaceuticals worth $45.5M as of Q2 2026.
- Swiss Life Asset Management bought 9,040 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.01M.
- Vertex Pharmaceuticals made up 0.19% of Swiss Life Asset Management's portfolio in Q2 2026, its #94 holding.
- Swiss Life Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
- 1,209 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.